TY - JOUR
T1 - α-Synuclein in blood cells differentiates Parkinson’s disease from healthy controls
AU - Abd Elhadi, Suaad
AU - Grigoletto, Jessica
AU - Poli, Maura
AU - Arosio, Paolo
AU - Arkadir, David
AU - Sharon, Ronit
N1 - Publisher Copyright: © 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Objective: To determine whether blood cells expressed α-Syn can differentiate Parkinson’s disease (PD) from healthy controls (HC). Methods: The concentrations of α-Syn were determined in samples of blood cell pellets using a quantitative Lipid-ELISA assay. In addition, the levels of total protein, hemoglobin, iron and H-ferritin were determined. The study includes samples from the Biofind cohort (n = 46 PD and 45 HC) and results were validated with an additional cohort (n = 35 PD and 28 HC). Results: A composite biomarker consisting of the concentrations of total α-Syn, proteinase-K resistant (PKres) α-Syn and phospho-Serine 129 α-Syn (PSer 129), is designed based on the analysis of the discovery BioFIND cohort. This composite biomarker differentiates a PD subgroup, presenting motor symptoms without dementia from a HC group, with a convincing accuracy, represented by an AUC = 0.81 (95% CI, 0.71 to 0.92). Closely similar results were obtained for the validation cohort, that is, AUC = 0.81, (95% CI, 0.70 to 0.94). Interpretation: Our results demonstrate the potential usefulness of blood cells expressed α-Syn as a biomarker for PD.
AB - Objective: To determine whether blood cells expressed α-Syn can differentiate Parkinson’s disease (PD) from healthy controls (HC). Methods: The concentrations of α-Syn were determined in samples of blood cell pellets using a quantitative Lipid-ELISA assay. In addition, the levels of total protein, hemoglobin, iron and H-ferritin were determined. The study includes samples from the Biofind cohort (n = 46 PD and 45 HC) and results were validated with an additional cohort (n = 35 PD and 28 HC). Results: A composite biomarker consisting of the concentrations of total α-Syn, proteinase-K resistant (PKres) α-Syn and phospho-Serine 129 α-Syn (PSer 129), is designed based on the analysis of the discovery BioFIND cohort. This composite biomarker differentiates a PD subgroup, presenting motor symptoms without dementia from a HC group, with a convincing accuracy, represented by an AUC = 0.81 (95% CI, 0.71 to 0.92). Closely similar results were obtained for the validation cohort, that is, AUC = 0.81, (95% CI, 0.70 to 0.94). Interpretation: Our results demonstrate the potential usefulness of blood cells expressed α-Syn as a biomarker for PD.
UR - http://www.scopus.com/inward/record.url?scp=85075472110&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/acn3.50944
DO - https://doi.org/10.1002/acn3.50944
M3 - مقالة
C2 - 31742923
SN - 2328-9503
VL - 6
SP - 2426
EP - 2436
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 12
ER -